Preparation and in vitro evaluation of hydrophilic fenretinide nanoparticles

International Journal of Pharmaceutics

Volumn 479, Issue 2, 2015, Pages 329-337

  Ledet, Grace A ^a   Graves, Richard A ^a   Glotser, Elena Y ^a   Mandal, Tarun K ^a   Bostanian, Levon A ^a  

^a XAVIER UNIVERSITY OF LOUISIANA   (United States)

Author keywords

Fenretinide; Formulation; Nanoparticles; Permeability; PVP

Indexed keywords

DICHLOROMETHANE; FENRETINIDE; METHANOL; NANOCARRIER; POVIDONE; WATER; ANTINEOPLASTIC AGENT; DRUG CARRIER; NANOPARTICLE;

ARTICLE; CACO 2 CELL LINE; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG FORMULATION; DRUG RELEASE; EVAPORATION; FREEZE DRYING; IN VITRO STUDY; INTESTINE MUCOSA PERMEABILITY; MELTING POINT; NANOENCAPSULATION; NANOFABRICATION; NANOPHARMACEUTICS; PARTICLE SIZE; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SOLVENT EXTRACTION; X RAY POWDER DIFFRACTION; CHEMICAL PHENOMENA; CHEMISTRY; COMPARATIVE STUDY; HUMAN; MEDICINAL CHEMISTRY; PERMEABILITY; PROCEDURES; SOLUBILITY; X RAY DIFFRACTION;

ANTINEOPLASTIC AGENTS; CACO-2 CELLS; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; FENRETINIDE; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; PARTICLE SIZE; PERMEABILITY; POVIDONE; SOLUBILITY; X-RAY DIFFRACTION;

EID: 84921044741     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2014.12.052     Document Type: Article

References (45)

1. A.U. Andar, R.R. Hood, W.N. Vreeland, D.L. Devoe, and P.W. Swaan Microfluidic preparation of liposomes to determine particle size influence on cellular uptake mechanisms Pharm. Res. 31 Feb 2 2014 401 413 10.1007/s11095-013-1171-8 PubMed PMID 24092051
2. S.T. Buckley, S.M. Fischer, G. Fricker, and M. Brandl In vitro models to evaluate the permeability of poorly soluble drug entities: challenges and perspectives Eur. J. Pharm. Sci. 45 3 2012 235 250 10.1016/j.ejps.2011.12.007 PubMed PMID 22178532
3. X. Cai, A. Walker, C. Cheng, A. Paiva, Y. Li, J. Kolb, J. Herbst, W. Shou, and H. Weller Approach to improve compound recovery in a high-throughput Caco-2 permeability assay supported by liquid chromatography-tandem mass spectrometry J. Pharm. Sci. 101 8 2012 2755 2762 10.1002/jps.23194 PubMed PMID 22611052
4. Children's Oncology Group (CCG 09709), J.G. Villablanca, M.D. Krailo, M.M. Ames, J.M. Reid, G.H. Reaman, and C.P. Reynolds Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709) J. Clin. Oncol. 24 21 2006 3423 3430 Erratum in: J. Clin. Oncol. 2006; 24(25): 4223. Reynolds, Patrick C [corrected to Reynolds, C Patrick]. PubMed PMID 16849757
5. N. Colombo, F. Formelli, M.G. Cantù, G. Parma, M. Gasco, A. Argusti, A. Santinelli, R. Montironi, E. Cavadini, L. Baglietto, A. Guerrieri-Gonzaga, G. Viale, and A. Decensi A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer Cancer Epidemiol. Biomarkers Prev. 15 10 2006 1914 1919 PubMed PMID 17035399
6. A. Dahan, H. Sabit, and G.L. Amidon Multiple efflux pumps are involved in the transepithelial transport of colchicine: combined effect of p-glycoprotein and multidrug resistance-associated protein 2 leads to decreased intestinal absorption throughout the entire small intestine Drug Metab. Dispos. 37 10 2009 2028 2036 10.1124/dmd.109.028282 PubMed PMID 19589874
7. A. Decensi, C. Robertson, A. Guerrieri-Gonzaga, D. Serrano, M. Cazzaniga, S. Mora, M. Gulisano, H. Johansson, V. Galimberti, E. Cassano, S.M. Moroni, F. Formelli, E.A. Lien, G. Pelosi, K.A. Johnson, and B. Bonanni Randomized double-blind 2 × 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women J. Clin. Oncol. 27 23 2009 3749 3756 10.1200/JCO.2008.19.3797 PubMed PMID 19597031
8. S.M. Fischer, M. Brandl, and G. Fricker Effect of the non-ionic surfactant Poloxamer 188 on passive permeability of poorly soluble drugs across Caco-2 cell monolayers Eur. J. Pharm. Biopharm. 79 2 2011 416 422 10.1016/j.ejpb.2011.04.010 PubMed PMID 21549839
9. K.J. Frank, U. Westedt, K.M. Rosenblatt, P. Hölig, J. Rosenberg, M. Mägerlein, M. Brandl, and G. Fricker Impact of FaSSIF on the solubility and dissolution-/permeation rate of a poorly water-soluble compound Eur. J. Pharm. Sci. 47 1 2012 16 20 10.1016/j.ejps.2012.04.015 PubMed PMID 22579958
10. A. Gombás, I. Antal, P. Szabó-Révész, S. Marton, and I. Erõs Quantitative determination of crystallinity of alpha-lactose monohydrate by near infrared spectroscopy (NIRS) Int. J. Pharm. 256 1-2 2003 25 32 PubMed PMID 12695008
11. B.C. Hancock, and G. Zografi Characteristics and significance of the amorphous state in pharmaceutical systems J. Pharm. Sci. 86 1 1997 1 12 PubMed PMID 9002452
12. W.F. Holmes, D.R. Soprano, and K.J. Soprano Synthetic retinoids as inducers of apoptosis in ovarian carcinoma cell lines J. Cell. Physiol. 199 3 2004 317 329 PubMed PMID 15095280
13. J. Jinno, N. Kamada, M. Miyake, K. Yamada, T. Mukai, M. Odomi, H. Toguchi, G.G. Liversidge, K. Higaki, and T. Kimura Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs J. Control. Release 111 1-2 2006 56 64 PubMed PMID 16410029
14. A. Kokate, X. Li, and B. Jasti Transport of a novel anti-cancer agent, fenretinide across Caco-2 monolayers Invest. New Drugs 25 3 2007 197 203 PubMed PMID 17146731
15. G. Krishna, K. Chen, C. Lin, and A.A. Nomeir Permeability of lipophilic compounds in drug discovery using in-vitro human absorption model, Caco-2 Int. J. Pharm. 222 1 2001 77 89 PubMed PMID 11404034
16. S. Kummar, M.E. Gutierrez, B.J. Maurer, C.P. Reynolds, M. Kang, H. Singh, S. Crandon, A.J. Murgo, and J.H. Doroshow Phase I trial of fenretinide lym-x-sorb oral powder in adults with solid tumors and lymphomas Anticancer Res. 31 3 2011 961 966 PubMed PMID 21498721
17. C.Y. Li, C.L. Zimmerman, and T.S. Wiedmann Solubilization of retinoids by bile salt/phospholipid aggregates Pharm. Res. 13 6 1996 907 913 PubMed PMID 8792431
18. H. Liu, C. Sabus, G.T. Carter, C. Du, A. Avdeef, and M. Tischler In vitro permeability of poorly aqueous soluble compounds using different solubilizers in the PAMPA assay with liquid chromatography/mass spectrometry detection Pharm. Res. 20 11 2003 1820 1826 PubMed PMID 14661927
19. N.L. Mata, J.B. Lichter, R. Vogel, Y. Han, T.V. Bui, and L.J. Singerman Investigation of oral fenretinide for treatment of geographic atrophy in age-related macular degeneration Retina 33 3 2013 498 507 10.1097/IAE.0b013e318265801d PubMed PMID 23023528
20. B.J. Maurer, O. Kalous, D.W. Yesair, X. Wu, J. Janeba, V. Maldonado, V. Khankaldyyan, T. Frgala, B.C. Sun, R.T. McKee, S.W. Burgess, W.A. Shaw, and C.P. Reynolds Improved oral delivery of N-(4-hydroxyphenyl) retinamide with a novel LYM-X-SORB organized lipid complex Clin. Cancer Res. 13 10 2007 3079 3086 PubMed PMID 17505011
21. R.C. Moon, H.J. Thompson, P.J. Becci, C.J. Grubbs, R.J. Gander, D.L. Newton, J.M. Smith, S.L. Phillips, W.R. Henderson, L.T. Mullen, C.C. Brown, and M.B. Sporn N-(4-Hydroxyphenyl) retinamide, a new retinoid for prevention of breast cancer in the rat Cancer Res. 39 4 1979 1339 1346 PubMed PMID 421218
22. M.M. Moore, M. Stockler, R. Lim, T.S. Mok, M. Millward, and M.J. Boyer A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group Cancer Chemother. Pharmacol. 66 5 2010 845 850 10.1007/s00280-009-1228-x PubMed PMID 20082080
23. A. Mukharya, S. Chaudhary, N. Mansuri, and A.K. Misra Solid-state characterization of lacidipine/PVP K(29/32) solid dispersion primed by solvent co-evaporation Int. J. Pharm. Invest. 2 2 2012 90 96 10.4103/2230-973X.100048 PubMed PMID 23119238
24. A.I. Niemczyk, A.C. Williams, C.F. Rawlinson-Malone, W. Hayes, B.W. Greenland, D. Chappell, O. Khutoryanskaya, and P. Timmins Novel polyvinylpyrrolidones to improve delivery of poorly water-soluble drugs: from design to synthesis and evaluation Mol. Pharm. 9 8 2012 2237 2247 10.1021/mp300079x PubMed PMID 22738427
25. S. Papadimitriou, and D. Bikiaris Dissolution rate enhancement of the poorly water-soluble drug Tibolone using PVP, SiO2, and their nanocomposites as appropriate drug carriers Drug Dev. Ind. Pharm. 35 9 2009 1128 1138 10.1080/03639040902787653 PubMed PMID 19555245
26. R.P. Patel, and M.M. Patel Physicochemical characterization and dissolution study of solid dispersions of lovastatin with polyethylene glycol 4000 and polyvinylpyrrolidone K30 Pharm. Dev. Technol. 12 1 2007 21 33 PubMed PMID 17484141
27. G.V. Patel, V.B. Patel, A. Pathak, and S.J. Rajput Nanosuspension of efavirenz for improved oral bioavailability: formulation optimization, in vitro, in situ and in vivo evaluation Drug Dev. Ind. Pharm. 40 1 2014 80 91 10.3109/03639045.2012.746362 PubMed PMID 23323843
28. R.D. Rao, M.A. Cobleigh, R. Gray, M.L. Graham 2nd, L. Norton, S. Martino, G.T. Budd, J.N. Ingle, and W.C. Wood Phase III double-blind, placebo-controlled, prospective randomized trial of adjuvant tamoxifen vs. tamoxifen and fenretinide in postmenopausal women with positive receptors (EB193): an intergroup trial coordinated by the Eastern Cooperative Oncology Group Med. Oncol. 28 suppl. 1 2011 S39 47 10.1007/s12032-010-9682-1 PubMed PMID 20878269
29. C.P. Reynolds Detection and treatment of minimal residual disease in high-risk neuroblastoma Pediatric Transplant. 8 5 2004 56 66 PubMed PMID 15125707
30. A.L. Sabichi, S.P. Lerner, E.N. Atkinson, H.B. Grossman, N.P. Caraway, C.P. Dinney, D.F. Penson, S. Matin, A. Kamat, L.L. Pisters, D.W. Lin, R.L. Katz, D.E. Brenner, G.P. Hemstreet 3rd, M. Wargo, A. Bleyer, W.H. Sanders, J.L. Clifford, H.L. Parnes, and S.M. Lippman Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer Clin. Cancer Res. 14 1 2008 224 229 10.1158/1078-0432.CCR-07-0733 PubMed PMID 18172274
31. B.J. Schneider, F.P. Worden, S.M. Gadgeel, R.E. Parchment, C.M. Hodges, J. Zwiebel, R.L. Dunn, A.J. Wozniak, M.J. Kraut, and G.P. Kalemkerian Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer Invest. New Drugs 27 6 2009 571 578 10.1007/s10637-009-9228-6 PubMed PMID 19225720
32. Y.F. Shealy, J.L. Frye, C.A. O'Dell, M.C. Thorpe, M.C. Kirk, W.C. Coburn Jr, and M.B. Sporn Synthesis and properties of some 13-cis- and all-trans-retinamides J. Pharm. Sci. 73 6 1984 745 751 PubMed PMID 6737257
33. K. Six, G. Verreck, J. Peeters, M. Brewster, and G. Van Den Mooter Increased physical stability and improved dissolution properties of itraconazole, a class II drug, by solid dispersions that combine fast- and slow-dissolving polymers J. Pharm. Sci. 93 1 2004 124 131 PubMed PMID 14648642
34. S.Y. Sun, W. Li, P. Yue, S.M. Lippman, W.K. Hong, and R. Lotan Mediation of N-(4-hydoxyphenyl) retinamide-induced apoptosis in human cancer cells by different mechanisms Cancer Res. 59 10 1999 2493 2498 PubMed PMID 10344763
35. T.T. Tran, A. Mittal, T. Gales, B. Maleeff, T. Aldinger, J.W. Polli, A. Ayrton, H. Ellens, and J. Bentz Exact kinetic analysis of passive transport across a polarized confluent MDCK cell monolayer modeled as a single barrier J. Pharm. Sci. 93 8 2004 2108 2123 PubMed PMID 15236458
36. T.T. Tran, P.H. Tran, and B.J. Lee Dissolution-modulating mechanism of alkalizers and polymers in a nanoemulsifying solid dispersion containing ionizable and poorly water-soluble drug Eur. J. Pharm. Biopharm. 72 1 2009 83 90 10.1016/j.ejpb.2008.12.009 PubMed PMID 19141319
37. U. Vaishampayan, L.K. Heilbrun, R.E. Parchment, V. Jain, J. Zwiebel, R.R. Boinpally, P. LoRusso, and M. Hussain Phase II trial of fenretinide in advanced renal carcinoma Invest. New Drugs 23 2 2005 179 185 PubMed PMID 15744595
38. R.B. van Breemen, and Y. Li Caco-2 cell permeability assays to measure drug absorption Expert Opin. Drug Metab. Toxicol. 1 2 2005 175 185 PubMed PMID 16922635
39. G. Van den Mooter, M. Wuyts, N. Blaton, R. Busson, P. Grobet, P. Augustijns, and R. Kinget Physical stabilisation of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25 Eur. J. Pharm. Sci. 12 3 2001 261 269 PubMed PMID 11113645
40. U. Veronesi, L. Mariani, A. Decensi, F. Formelli, T. Camerini, R. Miceli, M.G. Di Mauro, A. Costa, E. Marubini, M.B. Sporn, and G. De Palo Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer Ann. Oncol. 17 7 2006 1065 1071 PubMed PMID 16675486
41. J.G. Villablanca, W.B. London, A. Naranjo, P. McGrady, M.M. Ames, J.M. Reid, R.M. McGovern, S.A. Buhrow, H. Jackson, E. Stranzinger, B.J. Kitchen, P.M. Sondel, M.T. Parisi, B. Shulkin, G.A. Yanik, S.L. Cohn, and C.P. Reynolds Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group Clin. Cancer Res. 17 21 2011 6858 6866 10.1158/1078-0432.CCR-11-0995 PubMed PMID 21908574
42. W.N. William Jr, J.J. Lee, S.M. Lippman, J.W. Martin, N. Chakravarti, H.T. Tran, A.L. Sabichi, E.S. Kim, L. Feng, R. Lotan, and V.A. Papadimitrakopoulou High-dose fenretinide in oral leukoplakia Cancer Prev. Res. (Phila) 2 1 2009 22 26 10.1158/1940-6207.CAPR-08-0100 PubMed PMID 19139014
43. A. Xu, M. Yao, G. Xu, J. Ying, W. Ma, B. Li, and Y. Jin A physical model for the size-dependent cellular uptake of nanoparticles modified with cationic surfactants Int. J. Nanomed. 7 2012 3547 3554 10.2147/IJN.S32188 PubMed PMID 22848178
44. S. Yamashita, T. Furubayashi, M. Kataoka, T. Sakane, H. Sezaki, and H. Tokuda Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells Eur. J. Pharm.l Sci. 10 May 3 2000 195 204 PubMed PMID 10767597
45. L. Yu Amorphous pharmaceutical solids: preparation, characterization and stabilization Adv. Drug Deliv. Rev. 48 1 2001 27 42 PubMed PMID 11325475